Novelix Pharma.

Why is Novelix Pharmaceuticals Ltd falling/rising?

As of 17-Jul, Novelix Pharmaceuticals Ltd's stock price is declining at 63.26, down 4.89% and underperforming against the Sensex. Despite a year-to-date gain, recent trends show significant drops in both short-term and long-term investor interest, contributing to the stock's downward movement.

As of 17-Jul, Novelix Pharmaceuticals Ltd's stock price is falling, currently at 63.26, which reflects a change of -3.25 (-4.89%). The stock has underperformed compared to the benchmark Sensex, which has gained 0.75% over the past week, while Novelix has declined by 4.87%. Over the past month, the stock has experienced a significant drop of 24.68%, contrasting with a modest increase of 1.29% in the Sensex.<BR><BR>Despite a year-to-date gain of 1.02%, the stock's recent performance indicates a troubling trend, particularly with a 33.94% increase over the past year, which is overshadowed by its current decline. The stock has also shown a substantial increase over the last three and five years, with gains of 572.26% and 632.18%, respectively. However, the recent performance suggests a shift, as the stock has fallen for two consecutive days before showing a slight trend reversal today.<BR><BR>Investor participation appears to be declining, as evidenced by a delivery volume of 4.37k on 16 July, which is down by 43.91% compared to the five-day average. This decrease in trading volume may indicate reduced interest or confidence among investors, contributing to the stock's downward movement. Additionally, while the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, suggesting short-term weakness in price momentum. Overall, these factors collectively explain the current decline in Novelix Pharmaceuticals Ltd's stock price.

Which are the latest news on Novelix Pharma.?

How big is Novelix Pharma.?

As of 10th June, Novelix Pharmaceuticals Ltd has a market capitalization of 181.00 Cr and reported Net Sales of 4.40 Cr with a Net Profit loss of 2.17 Cr over the latest four quarters. Shareholder's Funds were 7.40 Cr, and Total Assets were 8.67 Cr as of March 2022.

As of 10th June, Novelix Pharmaceuticals Ltd has a market capitalization of 181.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 4.40 Cr. However, it experienced a loss of 2.17 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2022. Shareholder's Funds were recorded at 7.40 Cr, while Total Assets amounted to 8.67 Cr.

Who are in the management team of Novelix Pharma.?

The management team of Novelix Pharma includes Ravi Bhangadia (Chairman & Wholetime Director), Aditya Bhangadia (Managing Director), Arvind Kumar Bhangadia (Non-Executive Director), and independent directors Natwarlal Ramgopal Modani, Sagar Rajendra Karwa, and Monam Kapoor.

The management team of Novelix Pharma includes the following members:<BR><BR>1. **Ravi Bhangadia** - Chairman & Wholetime Director<BR>2. **ADITYA BHANGADIA** - Managing Director<BR>3. **Arvind Kumar Bhangadia** - Non Executive Director<BR>4. **Natwarlal Ramgopal Modani** - Independent Director<BR>5. **Sagar Rajendra Karwa** - Independent Director<BR>6. **Monam Kapoor** - Independent Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the Novelix Pharma.?

Novelix Pharma's peers include Khemani Distrib., M K Exim India, Jay Ambe Super., Ace Men, MRP Agro, Magson Retail, Silgo Retail, Purv Flexi, and Purple United. Novelix Pharma shows good growth and the highest 1-year return at 160.83%, while several peers exhibit below-average management risk and negative returns.

Peers: The peers of Novelix Pharma are Khemani Distrib., M K Exim India, Jay Ambe Super., Ace Men, MRP Agro, Magson Retail, Silgo Retail, Purv Flexi, and Purple United.<BR><BR>Quality Snapshot: Excellent management risk is observed at Khemani Distrib., M K Exim India, Jay Ambe Super., MRP Agro, and Purple United, while Below Average management risk is found at Novelix Pharma., Ace Men, Magson Retail, Silgo Retail, and Purv Flexi. Growth is Excellent at Jay Ambe Super. and Good at Novelix Pharma., Khemani Distrib., MRP Agro, and Purple United, while Below Average growth is seen at M K Exim India, Ace Men, Magson Retail, Silgo Retail, and Purv Flexi. Capital Structure is Excellent at M K Exim India, Good at Khemani Distrib., Jay Ambe Super., and MRP Agro, while Below Average capital structure is noted for Novelix Pharma., Ace Men, Magson Retail, Silgo Retail, and Purv Flexi.<BR><BR>Return Snapshot: Novelix Pharma. has the highest 1-year return at 160.83%, while M K Exim India has the lowest at -26.15%, indicating a strong performance compared to its peers. Additionally, Khemani Distrib., M K Exim India, Jay Ambe Super., MRP Agro, Ace Men, Magson Retail, Silgo Retail, and Purv Flexi all have negative six-month returns.

What does Novelix Pharma. do?

Novelix Pharmaceuticals Ltd is a micro-cap company in the retailing industry, reporting net sales of 25 Cr and a net profit of 1 Cr for March 2026. The company has a market cap of INR 181 Cr and a P/E ratio of 72.00.

Overview:<BR>Novelix Pharmaceuticals Ltd operates in the retailing industry as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Trimurthi Securities Limited' in 1994, underwent several name changes, and was last renamed to Novelix Pharmaceuticals Limited in 2025. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 25 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 181 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 72.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.06<BR>- Return on Equity: 9.96%<BR>- Price to Book: 7.08<BR><BR>Contact Details:<BR>Address: 4-4-231/1/2/ABC Inderbagh, Sultan Bazar Hyderabad Telangana : 500095<BR>Tel: 91-40-24757370<BR>Email: info@trimurthidrugs.com<BR>Website: http://www.trimurthidrugs.com

Should I buy, sell or hold Novelix Pharmaceuticals Ltd?

When is the next results date for Novelix Pharmaceuticals Ltd?

The next results date for Novelix Pharmaceuticals Ltd is 29 May 2026.

The next results date for Novelix Pharmaceuticals Ltd is scheduled for 29 May 2026.

Are Novelix Pharmaceuticals Ltd latest results good or bad?

Novelix Pharmaceuticals Ltd's latest results show a return to profitability with a net profit of ₹1.00 crore and record net sales of ₹48.40 crores; however, concerns about low Return on Equity, high P/E ratio, and a low Mojo Score suggest caution regarding its long-term prospects.

Novelix Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company has returned to profitability with a net profit of ₹1.00 crore in Q3 FY26, marking a significant turnaround from previous losses. Additionally, net sales reached ₹48.40 crores, the highest quarterly revenue in the company's history, which is a positive indicator of operational improvement.<BR><BR>However, despite these encouraging results, there are underlying concerns. The company's average Return on Equity (ROE) over the past five years is a mere 0.74%, indicating weak capital efficiency and a struggle to generate meaningful returns for shareholders. Furthermore, the stock's high P/E ratio of 114x suggests that it is currently overvalued relative to its earnings potential, raising questions about sustainability.<BR><BR>The company's Mojo Score is also low at 48 out of 100, leading to a "SELL" recommendation, reflecting ongoing concerns about its long-term fundamental strength. Additionally, the decline in promoter holding and the absence of institutional investors signal a lack of confidence in the company's future prospects.<BR><BR>In summary, while Novelix Pharmaceuticals has shown signs of recovery with its latest results, significant risks and valuation concerns remain, making the overall assessment cautious.

How has been the historical performance of Novelix Pharma.?

Novelix Pharma has experienced a declining trend in net sales and profitability, with significant losses reported since March 2020, including a net loss of -2.12 Cr in March 2022. Despite these challenges, the company's cash position improved, indicating some liquidity stability.

Answer:<BR>The historical performance of Novelix Pharma shows a declining trend in net sales and profitability over the past several years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Novelix Pharma's net sales have decreased from 10.50 Cr in March 2018 to 8.61 Cr in March 2022, reflecting a downward trend. The total operating income also followed this decline, dropping from 10.50 Cr in March 2018 to 8.61 Cr in March 2022. The company's total expenditure, excluding depreciation, peaked at 13.04 Cr in March 2021 but fell to 11.18 Cr in March 2022. Operating profit (PBDIT) has consistently been negative since March 2020, with a loss of -2.02 Cr reported in March 2022. Profit before tax and profit after tax also remained negative, with losses of -2.12 Cr and -2.12 Cr, respectively, in March 2022. The company's earnings per share (EPS) worsened from -0.01 in March 2017 to -2.22 in March 2022. Despite these challenges, the company's cash and cash equivalents improved from 0.59 Cr in March 2017 to 2.00 Cr in March 2022, indicating some liquidity stability. Overall, Novelix Pharma's financial performance has shown significant challenges, particularly in revenue generation and profitability, while maintaining a stable cash position.

Is Novelix Pharma. overvalued or undervalued?

As of November 27, 2025, Novelix Pharma is considered very expensive and overvalued with a PE ratio of 97.12, significantly higher than its peers, despite a strong stock performance of 148.52% over the past year.

As of 27 November 2025, the valuation grade for Novelix Pharma has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 97.12, an EV to EBIT of 70.40, and an EV to EBITDA of 68.28. These ratios are starkly higher than its peers, such as Sun Pharma with a PE of 37.62 and Divi's Lab at 69.34, both categorized as very expensive.<BR><BR>In comparison to its industry peers, Novelix Pharma's valuation metrics suggest it is not only overvalued but also out of sync with more attractively priced competitors like Cipla and Dr Reddy's Labs, which have PE ratios of 22.67 and 18.08, respectively. While Novelix has shown impressive stock performance over the past year with a return of 148.52% compared to the Sensex's 6.84%, this does not justify its current high valuation levels.

Who are the top shareholders of the Novelix Pharma.?

The top shareholders of Novelix Pharma are Srinidhi Fine-chemicals LLP with 38.67%, followed by Mallela Venkatramna Reddy at 11.6%, and individual investors holding 36.84%. There are currently no mutual funds or foreign institutional investors involved.

The top shareholders of Novelix Pharma include Srinidhi Fine-chemicals LLP, which holds the largest stake at 38.67%. The highest public shareholder is Mallela Venkatramna Reddy, who owns 11.6%. Additionally, individual investors collectively hold 36.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

What is the technical trend for Novelix Pharma.?

As of May 27, 2025, Novelix Pharma's technical trend is mildly bullish, supported by positive momentum from the MACD and RSI, although caution is advised due to a mildly bearish KST.

As of 27 May 2025, the technical trend for Novelix Pharma has changed from bullish to mildly bullish. The weekly MACD and RSI are both bullish, indicating positive momentum in the short term. The daily moving averages also reflect a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, while the Dow Theory indicates no trend weekly but mildly bullish monthly. Overall, the current stance is mildly bullish, supported by strong monthly indicators and daily moving averages, despite some mixed signals from the KST.